Form 4: Cytokinetics CEO Sells Shares
Insider Transaction (Form 4)
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 105,426 shares of common stock on September 14, 2026.
Summary
- Option exercise/conversion: acquired 7,500 Common Stock at $10.60 ($79,500) on September 14, 2026; holds 385,320 after (Direct).
- Open-market sale: disposed of 7,500 Common Stock at $73.44 ($550,800) on September 14, 2026; holds 377,820 after (Direct).
- Bona fide gift: disposed of 1,350 Common Stock on September 14, 2026; holds 376,470 after (Direct).
- Bona fide gift: disposed of 97,926 Common Stock on September 14, 2026; holds 278,544 after (Direct).
- Bona fide gift: acquired 97,926 Common Stock on September 14, 2026; holds 97,926 after (Indirect).
- Open-market sale: disposed of 97,926 Common Stock at $69.33 ($6,789,210) on September 15, 2026 (Indirect).
- Option exercise/conversion: disposed of 7,500 Non-Qualified Stock Option (Right to Buy) on September 14, 2026; holds 156,745 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $7,340,010 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Robert I Blum — Director, Officer (President & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-14 | Option exercise/conversion | Common Stock | 7,500 | $11 | $79.5K | 385,320 |
| 2026-09-14 | Open-market sale | Common Stock | 7,500 | $73 | $550.8K | 377,820 |
| 2026-09-14 | Bona fide gift | Common Stock | 1,350 | — | — | 376,470 |
| 2026-09-14 | Bona fide gift | Common Stock | 97,926 | — | — | 278,544 |
| 2026-09-14 | Bona fide gift | Common Stock | 97,926 | — | — | 97,926 |
| 2026-09-15 | Open-market sale | Common Stock | 97,926 | $69 | $6.8M | 0 |
| 2026-09-14 | Option exercise/conversion | Non-Qualified Stock Option (Right to Buy) | 7,500 | — | — | 156,745 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-14 | Option exercise/conversion (7,500 shares) |
| 2026-09-14 | Open-market sale (7,500 shares) |
| 2026-09-14 | Bona fide gift (1,350 shares) |
| 2026-09-14 | Bona fide gift (97,926 shares) |
| 2026-09-14 | Bona fide gift (97,926 shares) |
| 2026-09-15 | Open-market sale (97,926 shares) |
| 2026-09-14 | Option exercise/conversion (7,500 shares) |
Keywords
insider transaction, Form 4, CYTK, CYTOKINETICS INC, bearish, Robert I Blum
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.